Pregnancy outcomes following cabergoline treatment: extended results from a 12‐year observational study

  title={Pregnancy outcomes following cabergoline treatment: extended results from a 12‐year observational study},
  author={Annamaria Colao and Roger Abs and David Gonz{\'a}lez B{\'a}rcena and Philippe Chanson and Wolfgang Paulus and David L. Kleinberg},
  journal={Clinical Endocrinology},
Objective  Cabergoline is a dopamine agonist used to treat hyperprolactinaemia. Because hyperprolactinaemia is a significant cause of infertility in women, cabergoline and other dopamine agonists are frequently prescribed to reduce prolactin levels and restore normal menses. They are usually discontinued shortly after the patient becomes pregnant. Although cabergoline has been used to treat hyperprolactinaemia since the mid‐1990s, safety data related to maternal and foetal exposure to this… 

An observational study of pregnancy and post‐partum outcomes in women with prolactinoma treated with dopamine agonists

In women with prolactinoma medical treatment with dopamine agonists (DA) can restore fertility and the total number of reported cases remains modest and further evidence is needed.

High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy

Bromocriptine has extensive safety data in pregnancy, so it is the recommended first-line treatment in this scenario, although it might not always be well-tolerated or effective.

Dopamine agonists in the treatment of prolactinoma: are they still first choice?

The modern use of dopamine agonists in a patient with prolactinoma is discussed, with the possibility that these drugs may be associated with cardiac valvulopathy.

Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series

The safety of levodopa, pramipexole, rotigotine, and ropinirole in pregnancy is assessed.

Prolactinomas and pregnancy

The safety and efficacy of cabergoline compared to bromocriptine in women with prolactinomas who wish to become pregnant and the effects of the dopamine agonist on early foetal development and pregnancy outcomes are reported.

Cabergoline therapy for Macroprolactinoma during pregnancy: A case report

Cabergoline was able to safely treat macroprolactinemia in the authors' patient during pregnancy with cabergoline and the patient delivered a healthy baby.

Prolactinomas, cabergoline, and pregnancy

Even though BRC still remains the recommended DA drug for pregnancy induction or use during pregnancy in women with prolactinomas, increasing evidences point to the safety of CAB for this purpose.

2012 update in the treatment of prolactinomas.

Best Practice & Research Clinical Endocrinology & Metabolism

Should symptomatic tumor growth occur, reinstitution of the dopamine agonist is usually successful in shrinking the tumor but delivery if the pregnancy is sufficiently advanced is also an option and transsphenoidal debulking is rarely necessary.



Bromocriptine in pregnancy: Safety aspects

The results show that the use of Bromocriptine in the treatment of infertility in women is not associated with an increased risk of spontaneous abortion, multiple pregnancy or the occurrence of congenital malformation in their progeny.

Cabergoline: A first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma

The effectiveness and safety of CAB for patients with PRL-secreting pituitary adenoma are confirmed and it is suggested that it can be considered a first choice treatment.

Management of prolactinomas during pregnancy.

  • M. Molitch
  • Medicine
    The Journal of reproductive medicine
  • 1999
Preliminary evidence does not suggest any increase in adverse fetal outcomes and therapeutic abortion is not warranted if pregnancy occurs during cabergoline treatment, and the drug appears reasonably safe for continued use.

Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.

In the whole population, long-term control of hyperprolactinemia by quinagolide was obtained in 11/28 patients previously resistant to bromocriptine, and 15/20 women (75%) resumed normal gonadal function with a quinAGolide daily dose of 300 micrograms in most of them.

A Comparative Review of the Tolerability Profiles of Dopamine Agonists in the Treatment of Hyperprolactinaemia and Inhibition of Lactation

Cabergoline, a long-acting dopamine agonist administered once or twice weekly, has been shown to be significantly more effective than bromocriptine in suppressing prolactin secretion in hyperprolactinaemic patients, and is better tolerated, particularly in terms of nausea and vomiting.

Current treatment issues in female hyperprolactinaemia.

  • P. Crosignani
  • Medicine, Biology
    European journal of obstetrics, gynecology, and reproductive biology
  • 2006

Prolactinomas and Pregnancy

A non-hormonal contraceptive should be the use along with a DA drug until tumor shrinkage within sellar boundaries has been evidenced and the DA can be withdrawn and the patient must be closely followed.